Association between clinical use of lansoprazole and the risk of type 2 diabetes mellitus: a pharmacoepidemiological cohort study

Diabetology & Metabolic Syndrome

Research

Wen‐Tung Wu¹  Chien‐An Sun²  Yong-Chen Chen³  Ming-Hsun Lin⁴  Tsung-Kun Lin⁵  Yu‐Ching Chou⁶ 

[1]Department of Pharmacy, Tri-Service General Hospital, National Defense Medical Center, 114, Taipei City, Taiwan

[2]Department of Public Health, College of Medicine, Fu-Jen Catholic University, No.510, Zhongzheng Road, Xinzhuang District, 242, New Taipei City, Taiwan

[3]Department of Public Health, College of Medicine, Fu-Jen Catholic University, No.510, Zhongzheng Road, Xinzhuang District, 242, New Taipei City, Taiwan

[4]Department of Medicine, College of Medicine, Fu-Jen Catholic University, 242, New Taipei City, Taiwan

[5]Division of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, 114, Taipei City, Taiwan

[6]School of Pharmacy, National Defense Medical Center, 114, Taipei City, Taiwan

[7]School of Public Health, National Defense Medical Center, 114, Taipei City, Taiwan

关键词: Cohort studies;    Lansoprazole;    Proton pump inhibitors;    Type;    2 diabetes mellitus;   

DOI  :  10.1186/s13098-023-01051-8

 received in 2023-02-20, accepted in 2023-03-31,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundProton pump inhibitors (PPIs) are common and widely used for gastrointestinal-related disorders. Lansoprazole is one of PPIs with potential benefits of anti-inflammation, reduced oxidative stress, and anti-diabetes. The aims of this study are to determine whether lansoprazole imparts differential risk of type 2 diabetes as compared with other PPIs.MethodsA population-based retrospective cohort study was conducted using the National Health Insurance Research Database in Taiwan. Patients who received lansoprazole more than 90 days and without records of use of other PPIs between January 1, 2000 and December 31, 2005 (the exposure period) were considered as the exposed cohort (n = 1668). In comparison, patients who received other PPIs more than 90 days and without use of lansoprazole in the exposure period were treated as the comparison cohort (n = 3336).The primary outcome was the new-onset of type 2 diabetes mellitus (T2DM). The association between use of lansoprazole and the risk of T2DM was determined by hazard ratios (HRs) and 95% confidence intervals (CIs) derived from multivariable Cox proportional hazards models.ResultsThe lansoprazole cohort showed a significantly reduced risk of T2DM with an adjusted HR of 0.65 (95% CI 0.56–0.76). Interestingly, the inverse association between use of lansoprazole and risk of T2DM was observed in both genders and in various age groups.ConclusionThe present study findings suggest that lansoprazole was associated with a reduced risk of T2DM compared with other PPIs. Further studies are needed to determine the clinical implications of the present study.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2023_36_Article_IEq385.gif

Fig. 3